ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. The company specialises in high quality medicines for the treatment of important diseases in the livestock sector. ECO Animal Health are dedicated to the research, development and marketing of strong brands, differentiated generics and innovative new solutions.

19 Mar 2026

FY26 trading update: adj. EBITDA materially ahead

Revenue +8% YoY; FY26E raised to £86.0m (+3%)
North America lifted to £23.0m (+7% YoY); Latin America to £16.7m (+2%, reversing an 18% FY25 decline)
Gross margin nudged up to 45.5% on better pricing and input costs
Adj. EBITDA "materially ahead" of expectations; raised to £8.2m (12% YoY growth, 9.5% margin)
Forecasts raised across all three years
ECOVAXXIN® MS commercial launch across key European markets in 2026/27; peak revenue potential £22.2m
ECOVAXXIN® MG also in pipeline; peak revenue potential ~£10m
Fair Value raised to 180p/share — FY27 EV/EBITDA of 5.1x vs peer average of 13.5x

Download as a PDF file

Return to ECO Animal Health

Register to be first

Get research on the companies that interest you straight to your inbox

Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.

Equity Development Limited 3rd Floor, 80 Cheapside, London, EC2V 6EE

Website design & development by Breckenridge